66810-01-3

Basic information

• Product Name: 2-(4-BROMOPHENYL)-2-METHYLPROPANE-1,3-DIOL
• Synonyms: 2-(4-BROMOPHENYL)-2-METHYLPROPANE-1,3-DIOL;2-(4-bromophenyl)-2-methylpropane-1,3-dinol
• CAS NO: 66810-01-3
• Molecular Formula: C₁₀H₁₃BrO₂
• Molecular Weight: 245.11302
• Mol File: 66810-01-3.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(4-BROMOPHENYL)-2-METHYLPROPANE-1,3-DIOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-BROMOPHENYL)-2-METHYLPROPANE-1,3-DIOL(66810-01-3)
• EPA Substance Registry System: 2-(4-BROMOPHENYL)-2-METHYLPROPANE-1,3-DIOL(66810-01-3)

Safety Data

• Hazardous Substances Data: 66810-01-3(Hazardous Substances Data)

Usage

Class

Organic compound

Subcategory

Secondary alcohols and brominated compounds

Uses

Organic synthesis, pharmaceutical research, potential drug development, building block for complex organic compounds

Structural features

Chiral center, reactive

Reactivity

Capable of reacting in organic synthesis and pharmaceutical research

Upstream product

• 872882-98-9 diethyl 2-(4-bromophenyl)-2-methylmalonate 
• 14062-25-0 Ethyl 4-bromophenylacetate 
• 93139-85-6 2-(4-bromophenyl)malonic acid diethyl ester 
• 99-90-1 para-bromoacetophenone 
• 80909-78-0 p-bromo-α-methylstyrene oxide 
• 50-00-0 formaldehyd 
• 40460-91-1 2-(4-bromophenyl)propanal 
• 41841-16-1 (4-bromo-phenyl)-acetic acid methyl ester 
• 149506-35-4 2-(4-bromophenyl)-malonic acid dimethyl ester 

Downstream Products

• 66810-34-2 3-(4-bromophenyl)-3-methylthietane-1,1-dioxide 
• 66810-27-3 3-(4-bromophenyl)-3-methylthietane 
• 1431616-42-0 (4-(3-methyloxetan-3-yl)phenyl)boronic acid 
• 1431616-23-7 6-(4-(3-methyloxetan-3-yl)phenyl)nicotinonitrile 
• 872882-97-8 3-(4-bromophenyl)-3-methyloxetane 
• 161636-15-3 (Z)-4-(4-bromophenyl)-1,1,1-trifluoro-4-methoxybut-3-en-2-one 

Relevant articles and documents

Chemical space exploration of oxetanes

This paper focuses on new derivatives bearing an oxetane group to extend accessible chemical space for further identification of kinase inhibitors. The ability to modulate kinase activity represents an important therapeutic strategy for the treatment of h

MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.